Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 521,346
  • Shares Outstanding, K 57,040
  • Annual Sales, $ 177,980 K
  • Annual Income, $ -76,910 K
  • 36-Month Beta 0.97
  • Price/Sales 2.76
  • Price/Cash Flow N/A
  • Price/Book 2.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.77
  • Number of Estimates 3
  • High Estimate -0.52
  • Low Estimate -1.13
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.64 +16.62%
on 09/19/18
9.20 -3.20%
on 10/16/18
+1.30 (+17.08%)
since 09/17/18
3-Month
7.32 +21.72%
on 09/14/18
10.73 -17.00%
on 07/19/18
-1.58 (-15.06%)
since 07/17/18
52-Week
7.32 +21.72%
on 09/14/18
18.39 -51.55%
on 11/01/17
-9.28 (-51.02%)
since 10/17/17

Most Recent Stories

More News
Akebia Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2018 Annual Meeting

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 8.91 (-2.52%)
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Keryx Biopharmaceuticals, Inc. - KERX

NEW YORK, NY / ACCESSWIRE / October 8, 2018 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York...

KERX : 3.32 (-2.64%)
AKBA : 8.91 (-2.52%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Keryx Biopharmaceuticals, Inc. Merger

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors ("Board") of Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company")...

KERX : 3.32 (-2.64%)
AKBA : 8.91 (-2.52%)
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Keryx Biopharmaceuticals, Inc. - KERX

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Keryx Biopharmaceuticals,...

KERX : 3.32 (-2.64%)
AKBA : 8.91 (-2.52%)
Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error

Endo International (ENDP) recalls two lots of Robaxin 750mg Tablets due to wrong dosing information on the label.

ENDP : 17.05 (-6.83%)
AKBA : 8.91 (-2.52%)
CSBR : 12.39 (+3.86%)
BSTC : 61.10 (-0.99%)
Akebia Therapeutics to Participate in Upcoming Investor Conferences

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 8.91 (-2.52%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 8.91 (-2.52%)
Akebia Therapeutics to Participate in Upcoming Investor Conferences

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 8.91 (-2.52%)
Report: Exploring Fundamental Drivers Behind Oaktree Specialty Lending, uniQure N.V, Mercury, Akebia Therapeutics, Mitel Networks, and Greenlight Capital Re -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oaktree Specialty Lending Corp....

MITL : 11.02 (-0.09%)
QURE : 28.99 (+0.69%)
AKBA : 8.91 (-2.52%)
OCSL : 4.63 (-0.54%)
GLRE : 12.06 (+2.12%)
MRCY : 47.90 (-6.97%)
Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag

Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.

KERX : 3.32 (-2.64%)
ILMN : 328.96 (+0.73%)
AKBA : 8.91 (-2.52%)
GILD : 75.62 (-0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade AKBA with:

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 9.48
1st Resistance Point 9.19
Last Price 8.91
1st Support Level 8.57
2nd Support Level 8.24

See More

52-Week High 18.39
Fibonacci 61.8% 14.16
Fibonacci 50% 12.85
Fibonacci 38.2% 11.55
Last Price 8.91
52-Week Low 7.32

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar